Peptide News Digest

D&D Pharmatech + LG AI Research Peptide AI Partnership, Bloomberg Businessweek Peptide Gold Rush Feature, UCSD Semaglutide Epigenetic Aging Nature Communications, Azitra Cosmetic Peptide BIO 2026, Annals of Oncology 41% GLP-1 Cancer Risk Cut, Alabama Board Bans Research-Grade Peptides

D&D + LG AI lifts D&D 17%, Bloomberg gold-rush, UCSD semaglutide aging slowdown, Azitra +87%, Annals 41% cancer cut, Alabama bans research peptides.

6 stories · Covering industry, research, regulatory

Editor's Note

June 17 in the peptide field looked like a post-conference industry-and-policy day rather than a clinical-trials day. D&D Pharmatech and LG AI Research announced a joint AI-peptide drug-discovery partnership; LG AI's EXAONE Discovery platform will design oral peptide drug candidates while D&D contributes its oral peptide delivery experience, sending D&D shares up roughly 17%. Bloomberg Businessweek published an extended feature on the peptide gold rush, with Janoshik Analytical's Prague-based purity-testing operation reporting that peptide test volume grew 1,200% from 2023 to 2025 alongside the wellness market's mainstreaming. UC San Diego researchers reported a post hoc analysis of a randomized, placebo-controlled trial (Nature Communications, May 19, 2026) in which semaglutide slowed epigenetic aging by approximately 9% on the DunedinPACE clock and lowered PCGrimAge and PhenoAge estimates in 84 of the 108 adults with HIV-associated lipohypertrophy who were randomized. And small-cap Azitra (NYSE: AZTR) gained 87% on its June 16 announcement of a filaggrin-based protein and peptide program for cosmetic and cosmeceutical markets ahead of the BIO International Convention on June 23-25. Two backdated items worth surfacing: an Annals of Oncology paper published online June 7 reported that GLP-1 receptor agonists were associated with a 41% lower obesity-associated cancer risk in a 160,000-patient TriNetX target trial emulation; and the Alabama Board of Medical Examiners issued an official notice on May 26 prohibiting state-licensed physicians, PAs, CRNPs, and CNMs from prescribing non-FDA-approved research-grade peptides.

Correction (October 7, 2026): The UC San Diego semaglutide item originally said the trial randomized 84 adults and reported clock reductions in years; the trial randomized 108 people, 84 were analyzed, and the reductions are annualized rates in years per year. The item also gave GrimAge V1 a p-value of 0.02 instead of 0.042, did not say the epigenetic analysis was post hoc, and said a companion SLIM LIVER study published the same day replicated the results; that study was published April 21, 2026, was single-arm, and found no overall slowing on DunedinPACE or PCGrimAge. A closing sentence describing the data as anchoring a case for GLP-1 drugs as health-span extenders has been removed.

Industry

D&D Pharmatech and LG AI Research Announce Joint AI-Peptide Drug Discovery Partnership; D&D Shares Jump 17%

South Korea's D&D Pharmatech and LG AI Research announced June 17 a joint development agreement for AI-designed next-generation oral peptide drugs. LG AI Research will use its EXAONE Discovery pharmaceutical AI platform, which analyzes disease-causing protein structures to design optimal peptide sequences, while D&D contributes its oral peptide delivery experience and obesity-pipeline programs. D&D's shares closed up 16.59% on the announcement. The deal extends D&D's late-cycle pipeline momentum, following the April 2026 $1.3M Pfizer research contract on oral obesity peptides after Pfizer's Metsera acquisition, and the June ADA showcase of Korean monthly-GLP-1 programs.

#d-and-d-pharmatech #lg-ai-research #exaone-discovery #ai-drug-design #oral-peptide #korea #partnership
Industry

Bloomberg Businessweek (June 17): The Peptide Gold Rush — Black-Market Wellness Drugs Move Toward a Multibillion-Dollar Legitimate Industry

Bloomberg Businessweek published a long-form feature June 17 mapping the peptide gold rush as black-market wellness drugs move toward legitimacy ahead of the July 23-24 PCAC meeting. The piece centers on Janoshik Analytical, a Prague-based purity-testing operation that grew its peptide test volume by more than 1,200% from 2023 to 2025 and reports almost nine figures in annual revenue. Investor estimates put the current US black market at $1-3 billion. Bloomberg reports peptides are now being pitched to menopausal suburban moms and offered at med spas as a casual add-on to Botox, with FDA-regulated peptide pricing strategy now an active question for entrepreneurs, investors, and incumbents alike.

#bloomberg #peptide-gold-rush #black-market #janoshik #wellness-peptides #pcac #industry-feature
Research

Nature Communications (May 19): Semaglutide Slowed Epigenetic Aging by 9% on DunedinPACE Clock in a Post Hoc Analysis of a Phase 2b RCT in HIV-Associated Lipohypertrophy

Researchers at UC San Diego and partner institutions reported in Nature Communications on May 19, 2026 a post hoc, exploratory analysis of epigenetic aging in a 32-week, double-blind, placebo-controlled Phase 2b trial of semaglutide in adults with HIV-associated lipohypertrophy. The trial randomized 108 people; 84 with blood samples at baseline and week 32 were analyzed (semaglutide n=45, placebo n=39), and epigenetic aging was not a prespecified endpoint. Compared with placebo, semaglutide lowered annualized clock estimates for PhenoAge by 4.9 years per year (p=0.004), PCGrimAge by 3.1 (p=0.007), GrimAge V2 by 2.3 (p=0.009), and GrimAge V1 by 1.4 (p=0.042), and slowed DunedinPACE by about 9% (-0.09 units, p=0.01). The authors said the post hoc design, modest sample, HIV-specific population, and 32-week follow-up limit how widely the results apply.

#semaglutide #epigenetic-aging #dunedinpace #grimage #phenoage #healthspan #ucsd #nature-communications #longevity
Industry

Azitra (NYSE: AZTR) Gains 87% on June 16 Launch of Filaggrin Protein and Peptide Program for Cosmetic and Cosmeceutical Markets

Azitra, Inc. (NYSE American: AZTR), a clinical-stage precision-dermatology biotech, announced June 16 a strategic launch into the cosmetic and cosmeceutical markets with a new protein and peptide program built on proprietary filaggrin technologies and the company's microbial genetic-engineering platform. Cofounder and COO Travis Whitfill, Ph.D., MPH will present pipeline updates at the BIO International Convention in San Diego on June 23, 2026 at 4:45 PM PT. The stock gained 87% the same day on roughly 251x average trading volume, closing at $0.35. Filaggrin is a structural protein critical for skin-barrier function and a target of growing interest in barrier-repair cosmeceuticals.

#azitra #aztr #filaggrin #cosmetic-peptides #cosmeceutical #bio-international #precision-dermatology
Research

Annals of Oncology (June 7): GLP-1 RA Use Linked to 41% Lower Obesity-Associated Cancer Risk in 160,000-Patient TriNetX Target Trial Emulation

A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.

#glp-1 #cancer-prevention #obesity-associated-cancer #annals-of-oncology #trinetx #houston-methodist #asco-2026 #endometrial-cancer
Regulatory

Alabama Board of Medical Examiners Official Notice (May 26): Physicians, PAs, CRNPs, and CNMs Prohibited From Prescribing Non-FDA-Approved Research-Grade Peptides

The Alabama Board of Medical Examiners and Medical Licensure Commission issued a formal notice on May 26, 2026 prohibiting physicians, physician assistants, certified registered nurse practitioners, and certified nurse midwives from prescribing, administering, dispensing, recommending, or supplying any non-FDA-approved research-grade peptide to a patient. The notice explicitly declares patient consent forms acknowledging research-grade status ineffective and unable to mitigate professional or legal liability. Chairman Rogers cited the lack of FDA review as the basis: substances that have not gone through FDA review cannot be reliably verified for identity, manufacturing process, or risk profile. The state-level prohibition arrived alongside the FDA's April 22 removal of 12 peptides from Category 2 ahead of the July 23-24 PCAC meeting, illustrating that state-board enforcement is now layering on top of federal regulatory action.

#alabama #state-medical-board #research-grade-peptides #non-fda-approved #physician-licensure #enforcement #compounding

Related Guides